Trial result ·
Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study looked at brepocitinib, a drug taken by mouth, for dermatomyositis. It was a planned extra look at data from a trial called VALOR. The trial ran for 52 weeks at 90 sites in 20 countries, with 241 people. All were adults with active skin and muscle disease. By chance, they got brepocitinib 30 mg, brepocitinib 15 mg, or a dummy pill daily. Neither the people nor the study staff knew who got which.
What they found
From week 4, skin disease eased more on 30 mg than on the dummy pill. More people on 30 mg had a meaningful skin response: 27 versus 14. More had their itch nearly gone, 31 versus 15, and better skin-related life quality. These gains held at every check from week 4 to week 52. With moderate to severe skin disease, 21 on 30 mg versus 12 had near-clear skin. Safety was in line with approved drugs of the same kind.
What it means for patients
The authors say 30 mg once a day gave fast, lasting control of skin disease. They describe this control as reaching remission level. They judged the safety of the drug to be acceptable.
Why it is not certain yet
This report is a secondary look at data from one trial. Some results, like itch and life quality, were only explored, not key goals. The near-clear skin results come only from people with moderate to severe skin disease. The abstract does not give full details on side effects. It also does not give skin results for the 15 mg dose.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.
PubMed · PMID 42646746We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Dermatomyositis and polymyositis (myositis) publications